[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Kawamura N, Kakuta Y, Fukuhara S, Imazui T, Hara T, Yamaguchi S, Adachi S, Nonomura N, Nagahara A: [A case of paratesticular rhabdomyosarcoma]. Hinyokika Kiyo; 2008 Jun;54(6):431-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of paratesticular rhabdomyosarcoma].
  • We report a case of paratesticular rhabdomyosarcoma in a 16-year-old male.
  • The patient with a mass in the right scrotum was at first diagnosed with testicular tumor.
  • Right orchiectomy revealed paratesticular rhabdomyosarcoma.
  • Para-aortic lymph node metastasis was pointed out by abdominal computed tomography.
  • Although he received multidrug chemotherapy consisting of vincristine, adriamycin, cyclophosphamide, cisplatin, and actinomycin-D (IRS-III regimen 35 and IRS-IV regimen) without radiotherapy, he died twenty-one months after the operation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634441.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


2. Ugwumba FO, Okafor OC, Nnakenyi EF, Nnabugwu II, Mbadiwe OM: Paratesticular myxoid liposarcoma in a 23-year old Nigerian. Rare Tumors; 2010;2(2):e23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular myxoid liposarcoma in a 23-year old Nigerian.
  • Paratesticular liposarcomas are rare tumors and are usually seen in patients in middle age or older.
  • Optimal treatment is radical orchidectomy.
  • Radiotherapy or chemotherapy is added for advanced disease or recurrences.
  • These practice guidelines often vary from the experience in developing countries.We present a 23-year old man who presented with paratesticular myxoid liposarcoma, after transscrotal orchidectomy for 'testicular tumor' without histology.
  • He was subsequently managed by neoadjuvant chemotherapy and complete tumor excision.A case of paratesticular myxoid liposarcoma in a young man is highlighted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139825.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994516
  • [Keywords] NOTNLM ; 23-year old / Nigerian. / myxoid liposarcoma / paratesticular
  •  go-up   go-down


3. Tomobe M, Miyanaga N, Kawai K, Kikuchi K, Uchida K, Takeshima H, Hasegawa Y, Nagasawa T, Akaza H: [Intrascrotal tumors: a clinicopathologic study of 15 cases]. Nihon Hinyokika Gakkai Zasshi; 2000 Sep;91(9):618-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor weight ranged from 2 to 200 g, with an average of 104.6 g.
  • The histological diagnoses of 15 patients were 8 malignant lymphomas, 2 paratesticular rhabdomyosarcomas, 2 metastatic tumors (origin; stomach and prostate), 1 epidermoid cyst, 1 cyst of tunica testis, and 1 adenomatoid tumor.
  • Five 8 patients died in spite of systemic chemotherapy after an orchiectomy, whereas 2 cases with metastatic tumors died of primary cancer, and two cases with paratesticular rhabdomyosarcoma are still alive and have had no evidence of disease.
  • Therefore, accurate diagnosis and precise treatment is important in the patient with intrascrotal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11068425.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


Advertisement
4. Arocena García Tapia J, Sanz Pérez G, Diez-Caballero Alonso F, Fernández FJ, Martín-Marquina Aspiunza A, Rodríguez-Rubio Cortadellas F, Rosell Costa D, Robles García JE, Zudaire Bergera JJ, Berián Polo JM: [Epididymal carcinoma. Bibliographic review in reference to a case]. Arch Esp Urol; 2000 Apr;53(3):273-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe a case of epithelial cell paratesticular carcinoma of the epididymis and briefly review the literature on this tumor type.
  • The patient did not respond to chemotherapy.
  • He developed systemic metastasis and died 4 months after the diagnosis.
  • CONCLUSIONS: Carcinoma of the epididymis is a rare malignant paratesticular tumor arising from the epithelial cells with a very poor prognosis.
  • Its clinical features are unspecific and this tumor type should be taken into account when making differential diagnosis from intrascrotal masses arsing from other causes.
  • Due to the rarity of this disease, it has not been possible to identify treatments that might achieve better results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10851737.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] SPAIN
  • [Number-of-references] 9
  •  go-up   go-down


5. Cruz Guerra NA, Clemente Ramos L, Montáns Araújo J, Linares Quevedo A, Pozo Mengual B, Allona Almagro A: [Paratesticular leiomyosarcoma: report of a new case]. Arch Esp Urol; 2002 Apr;55(3):311-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paratesticular leiomyosarcoma: report of a new case].
  • [Transliterated title] Leiomiosarcoma paratesticular: descripción de un nuevo caso.
  • OBJECTIVE: To report an additional case of paratesticular leiomyosarcoma.
  • Physical examination showed a mass involving the distal right spermatic cord and was confirmed by ultrasound and CT.
  • RESULTS: Histopathological and immunohistochemical studies demonstrated a well-differentiated paratesticular leiomyosarcoma.
  • Complete excision of the tumorous tissue was performed with no other adjuvant therapy.
  • CONCLUSIONS: This tumor type is uncommon.
  • Like other authors, we believe that orchifuniculectomy is the treatment of choice.
  • Furthermore, adjuvant radio or chemotherapy does not significantly influence survival in these patients.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12068764.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Uría González-Tova J, Escalera Almendros C, Sánchez Macias J, Areal Calama J, Sanfeliú Cortes F, Ibarz Servio L, Saladie Roig JM: [Malignant mesothelioma of the tunica vaginalis]. Actas Urol Esp; 2000 Oct;24(9):757-60
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient undergoes chemotherapy and radiotheraphy with a poor prognose.
  • We review the diagnosis, histopathology and therapeutical approach for this uncommon kind of paratesticular tumor (less than 80 cases reported in the last 30 years).

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11132449.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Downes KA, Goldblum JR, Montgomery EA, Fisher C: Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases. Mod Pathol; 2001 Mar;14(3):179-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In each case, the following features were noted: tumor site; tumor size; tumor depth; predominant histologic pattern (epithelioid or malignant fibrous histiocytoma [MFH]-like); extent of necrosis (absent, less than 15%, or at least 15%); mitotic counts; treatment and clinical follow-up.
  • Tumors involved the extremities (13 patients: intramuscular in 10, subcutaneous in 2, depth unknown in 1), retroperitoneum (4 patients), mediastinum (1 patient), and paratesticular region (1 patient).
  • All patients were treated surgically; 10 patients received adjuvant chemotherapy and/or radiation therapy.
  • On follow-up of 18 patients (range, 2--129 mo; mean, 35.4 mo; median, 23 mo) nine (50%) were dead of disease (range, 2--48 mo; mean, 20.1 mo; median, 12 mo), one died of other causes 2 months after diagnosis, two were alive with disease, five were disease free, and one was alive at 129 months (tumor status unknown).
  • Metastases developed in eight patients (range, 4--48 mo; mean, 19.5 mo; median, 11.5 mo), most commonly to the lungs.
  • In conclusion, pleomorphic liposarcoma is a rare tumor of adulthood that occurs most commonly in the deep, soft tissues of the extremities.
  • Although this tumor has a wide range of histologic appearances, no clinical or pathologic feature is predictive of a more aggressive clinical course.
  • [MeSH-major] Liposarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Necrosis. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11266523.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Mamveev BP, Gurariĭ LL, Volkova MI, Matveev VB, Khalaf'ian EA: [Paratesticular rhabdomyosarcoma]. Urologiia; 2003 Mar-Apr;(2):18-21
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paratesticular rhabdomyosarcoma].
  • Paratesticular rabdomyosarcoma (PR), the most frequently occurring paratesticular tumor, is encountered mostly in young and middle-aged men.
  • PR metastasizes early and is characterized by lymphogenic dissemination of the tumor with affection of the retroperitoneal lymph nodes.
  • Orchofuniculectomy is the first-line treatment in all the patients.
  • In disseminated PR, combined treatment is indicated including surgical removal of metastatic foci and adjuvant chemo- or chemoradiotherapy.
  • If surgical removal of all the tumor foci is infeasible, patients with disseminated PR undergo chemotherapy.
  • Prognosis of PR depends on the age, stage of the disease and treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12811918.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


9. Sha JJ, Lu JW, Zhu JS, Huang XY, Wang YX: [Desmoplastic small round-cell tumor of the paratesticular region: a case report and review of the literature]. Zhonghua Nan Ke Xue; 2007 Oct;13(10):918-20
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoplastic small round-cell tumor of the paratesticular region: a case report and review of the literature].
  • OBJECTIVE: To investigate the clinical and pathological features of paratesticular desmoplastic small round cell tumor (DSRCT), and to improve the diagnosis and treatment of the disease.
  • METHODS: One case of paratesticular DSRCT was studied retrospectively and a considerable amount of related literature from Medline and Chinese journals reviewed.
  • RESULTS: During the operation the paratesticular area was found full of multiple nodular tumor masses of various sizes ranging from 0.5 cm to 1.5 cm in diameter.
  • The tumor presented an immunohistochemical feature of epithelial, mesenchymal as well as neural multidirectional differentiation.
  • Following testicular tumor orchiectomy, chemotherapy was performed with DDP, VP16, ifosfamide and EPI.
  • Three years follow-up found no tumor recurrence.
  • CONCLUSION: Desmoplastic small round cell tumor has a specific clinicopathologic stigmata, usually occurring in young males, for which surgical resection with chemotherapy is the treatment of choice.
  • DSRCT located in the paratesticular region may have a better prognosis than its more frequently abdominal counterpart.
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17977326.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 13
  •  go-up   go-down


10. Agarwal PK, Palmer JS: Testicular and paratesticular neoplasms in prepubertal males. J Urol; 2006 Sep;176(3):875-81
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular and paratesticular neoplasms in prepubertal males.
  • PURPOSE: We reviewed the current diagnosis, staging and management of testicular and paratesticular neoplasms in prepubertal males.
  • MATERIALS AND METHODS: We performed a medical literature search in English using MEDLINE/PubMed that addressed testicular and/or paratesticular neoplasms in prepubertal males.
  • A palpable, nontender mass suggests the diagnosis and prompts scrotal ultrasound and tumor markers.
  • Although treatment for most primary tumors has historically been radical inguinal orchiectomy, most benign tumors can now be managed by testis sparing surgery.
  • The addition of radiation, chemotherapy and/or retroperitoneal lymph node dissection depends on tumor stage and histological type.
  • CONCLUSIONS: Although it is rare in children, any solid scrotal mass in prepubertal males warrants evaluation for possible testicular or paratesticular neoplasm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890643.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


11. Tröbs RB, Körholz D, Bennek J: Outcome of paratesticular involvement in infants with neuroblastoma. J Pediatr Surg; 2001 Dec;36(12):E23
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of paratesticular involvement in infants with neuroblastoma.
  • The authors report on 3 infants suffering from disseminated neuroblastoma (NB) involving the testes or paratesticular structures.
  • One patient with a stage 4 NB died of tumor progression; one patient is under therapy.
  • The patient with NB 4S was cured with preservation of both testes after antineoplastic chemotherapy and reduction of the retroperitoneal primary.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Humans. Infant. Male. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11733935.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Aydin GB, Ciftçi AO, Yalçin B, Akçören Z, Cağlar M, Senocak ME, Büyükpamukçu M: Paratesticular metastasis from Wilms tumor associated with a hydrocele. Pediatr Blood Cancer; 2006 Jul;47(1):97-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular metastasis from Wilms tumor associated with a hydrocele.
  • Metastatic sites other than the lungs, lymph nodes, and liver are unusual for Wilms tumor (WT).
  • We report a 3-year-old boy with stage IIA WT, who experienced paratesticular metastasis 2 months after surgery for an abdominal recurrence.
  • The patient underwent right radical orchiectomy, and pathological examination revealed paratesticular WT metastasis.
  • We considered that tumor cells spread through the patent processus vaginalis and grew at paratesticular space in hydrocele.
  • One month after the end of 12 months of salvage chemotherapy and abdominal radiotherapy, the patient has no evidence of disease.
  • [MeSH-major] Genital Neoplasms, Male / secondary. Neoplasm Recurrence, Local / pathology. Testicular Hydrocele / etiology. Wilms Tumor / pathology
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Humans. Male. Orchiectomy. Testicular Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16049972.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


13. Cao Avellaneda E, Alarcón Martínez H, Fuster Soler JL, López Cubillana P, Llinares Riestra E, Pérez Albacete M: [Testicular and paratesticular prepuberal tumors: our experience and update on the topic]. Actas Urol Esp; 2005 Apr;29(4):355-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular and paratesticular prepuberal tumors: our experience and update on the topic].
  • OBJECTIVES: To evaluate the importance of testicular and paratesticular prepubertal tumors in our center and to make an update on the topic.
  • METHODS AND PATIENTS: Data from all patients diagnosed of testicular and paratesticular prepubertal tumors and treated in our pediatric oncology unit from January 1st 1998 to December 31st 2003 have been revised.
  • RESULTS: Seven cases are reported among one hundred and ninety patients (represents 3,68 percent of all treated tumors): five tumors affecting the testis and two cases of paratesticular tumors.
  • Pathology classification was as follows: one yolk sack tumor, one mature teratoma, two nongerminomatous testicular tumors (one Sertoli cell tumor and one unclassifiable), one Burkitt's lymphoma and two paratesticular rhabdomyosarcomas.
  • Primary approach was inguinal radical orchiectomy in all cases except neoadjuvant chemotherapy in the case of lymphoma and partial escrotectomy in one patient previously managed with transcrotal orchiectomy.
  • Rhabdomyosarcoma cases received adjuvant chemotherapy.
  • CONCLUSIONS: Testicular and paratesticular prepubertal tumors are rare.
  • Except for one patient affected of lymphoma, surgical primary approach have been essential for treatment.
  • [MeSH-minor] Child. Humans. Infant. Male. Neoplasm Staging. Orchiectomy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981422.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Kalyvas KD, Kotakidou R, Trantos A, Yannakoyorgos K, Hatzichristou DG: Paratesticular well-differentiated, adipocytic type liposarcoma presenting as inguinal hernia. Urol Int; 2004;72(3):264-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular well-differentiated, adipocytic type liposarcoma presenting as inguinal hernia.
  • Paratesticular masses can pose difficult diagnostic and therapeutic problems to the physician.
  • We report a rare case of paratesticular liposarcoma with the clinical symptomatology of an inguinal hernia.
  • The treatment was surgical and included radical orchiectomy and wide excision of the tumor mass to the macroscopically healthy margins.
  • We review the literature, and discuss the role of radical orchiectomy, radiation, and chemotherapy in the treatment of paratesticular liposarcomas.

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 15084775.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 17
  •  go-up   go-down


15. García-González J, Villanueva C, Fernández-Aceñero MJ, Paniagua P: Paratesticular desmoplastic small round cell tumor: case report. Urol Oncol; 2005 Mar-Apr;23(2):132-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular desmoplastic small round cell tumor: case report.
  • BACKGROUND: The desmoplastic small round cell tumor has recently been separated from other small round cell tumors because of its characteristic pathological and clinical features.
  • However, in recent years there have reports on desmoplastic small round cell tumors affecting other body regions, including the paratesticular area.
  • Physical examination revealed a round elastic firm 2 to 3 cm mass distal to the tail of the epididymis, which was excised with a preoperative diagnosis of adenomatoid tumor.
  • However, histological and immunohistochemical diagnosis confirmed a desmoplastic small round cell tumor.
  • The extension study included a computed tomography scan and a plain chest radiograph, that showed no metastasis.
  • The patient received chemoradiation therapy with methotrexate, dacarbacin, cyclophosphamide, actinomycin D and vincristin, but had to be changed to a vincristin, actinomycin D, cyclophosphamide and adriamicin scheme on severe toxicity.
  • He completed five cycles of the chemotherapy with moderate toxicity.
  • CONCLUSIONS: Recent reviews on desmoplastic small round cell tumor affecting the paratesticular area have shown a better prognosis for tumors of this origin compared to abdominal ones.
  • We should include this lesion among the differential diagnosis of paratesticular tumors, mainly in children and adolescents.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Humans. Male

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869999.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Calonge WM, Heitor F, Castro LP, Meruje M, Coutinho SP, Cunha C, Ochoa de Castro A: Neonatal paratesticular neuroblastoma misdiagnosed as in utero torsion of testis. J Pediatr Hematol Oncol; 2004 Oct;26(10):693-5
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal paratesticular neuroblastoma misdiagnosed as in utero torsion of testis.
  • Primary paratesticular neuroblastomas seem even rarer, and only five infants with this condition have been previously described.
  • To the authors' knowledge, this would be the first report of a neonatal congenital paratesticular neuroblastoma.
  • Surgery showed a paratesticular mass with a small attachment to an intra-abdominal epiploon.
  • As the tumor was classified as International Neuroblastoma Staging System stage I, no additional chemotherapy was administered.
  • The patient was tumor-free at 11 months follow-up.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Infant, Newborn. Karyotyping. Male. Phosphopyruvate Hydratase / analysis. Remission Induction. S100 Proteins / analysis. Spermatic Cord / pathology. Synaptophysin / analysis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15454846.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 7
  •  go-up   go-down


17. Montgomery E, Fisher C: Paratesticular liposarcoma: a clinicopathologic study. Am J Surg Pathol; 2003 Jan;27(1):40-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular liposarcoma: a clinicopathologic study.
  • Paratesticular liposarcomas are rare and typically reported as isolated cases or as components of larger studies of liposarcomas.
  • All cases of paratesticular liposarcomas were retrieved from the archives of the Royal Marsden Hospital and the Johns Hopkins Hospital.
  • There were 30 paratesticular liposarcomas from men aged 41-87 years (mean 63 years; median 65 years) that involved the spermatic cord (23, 76%), testicular tunics (6, 20%), and epididymis (1, 4%).
  • One patient with WDL received radiation after his second recurrence and the myxoid/round cell liposarcoma received radiation and chemotherapy.
  • Only one example of DDL recurred, at 30 months; another patient, who refused therapy for 15 years, had a primary tumor 30 cm in diameter, displayed pulmonary metastases 1 month after excision, and died after 14 months.
  • In summary, paratesticular WDL had a prolonged course with recurrences in more than half the cases, sometimes late.
  • One DDL recurred and only one of five (20%) developed metastases, but the mean follow-up for DDL was only 24 months.

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12502926.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ferrari A, Bisogno G, Casanova M, Meazza C, Piva L, Cecchetto G, Zanetti I, Pilz T, Mattke A, Treuner J, Carli M: Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. J Clin Oncol; 2002 Jan 15;20(2):449-55
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group.
  • PURPOSE: We report the experience of the German-Italian Cooperative Group with 216 pediatric patients with paratesticular rhabdomyosarcoma treated over 20 years.
  • Among the nonmetastatic patients, complete tumor resection was performed in 83% of cases.
  • All patients received chemotherapy, which was reduced in intensity and duration for patients with low-risk features in subsequent protocols.
  • RESULTS: Among 72 patients with a negative retroperitoneal computed tomography (CT) scan, surgical assessment detected nodal involvement in only one case.
  • Retroperitoneal nodal recurrence was the major cause of treatment failure.
  • Univariate analysis revealed the prognostic value of tumor invasiveness, size, and resectability, as well as of nodal involvement and age, in patients with localized tumor.
  • CONCLUSION: The outcome for patients with localized paratesticular rhabdomyosarcoma is excellent, despite the reduction in chemotherapy over the years: an alkylating agent-free and anthracycline-free regimen is adequate treatment for low-risk patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / pathology. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11786573.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Kourda N, El Atat R, Derouiche A, Bettaib I, Baltagi S, Zermani R: [Paratesticular pleomorphic rhabdomyosarcoma in an adult: diagnosis and management]. Cancer Radiother; 2007 Sep;11(5):280-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paratesticular pleomorphic rhabdomyosarcoma in an adult: diagnosis and management].
  • A paratesticular pleomorphic rhabdomyosarcoma occurring in a 63-year old man is reported.
  • Clinical signs were like any intrascrotal tumor.
  • The patient developed a local recurrence, which was treated by radiotherapy, and subsequently developed metastases two years later, which were treated by chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Follow-Up Studies. Humans. Immunohistochemistry. Lung Neoplasms / drug therapy. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Orchiectomy. Radiotherapy Dosage. Testis / pathology. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611140.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Grüschow K, Kyank U, Stuhldreier G, Fietkau R: Surgical repositioning of the contralateral testicle before irradiation of a paratesticular rhabdomyosarcoma for preservation of hormone production. Pediatr Hematol Oncol; 2007 Jul-Aug;24(5):371-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical repositioning of the contralateral testicle before irradiation of a paratesticular rhabdomyosarcoma for preservation of hormone production.
  • A then 16-year-old boy developed a right paratesticular embryonal rhabdomyosarcoma in 2003.
  • Initial treatment consisted of orchiectomy and chemotherapy.
  • Hyperfractionated, accelerated radiation therapy was administered to a total dose of 44.0 Gy.
  • No clinical abnormalities or signs of tumor had been observed as of June 2006.
  • [MeSH-major] Hormones / biosynthesis. Radiotherapy / methods. Rhabdomyosarcoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Humans. Male. Testis / surgery

  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613883.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hormones
  •  go-up   go-down


21. Rais H, Elmansouri F, Belaabidia B, Essadki O, Oussehal A, Sarf I: [Paratesticular desmoplastic small round cell tumour: case report with literature review]. Cancer Radiother; 2010 Apr;14(2):111-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paratesticular desmoplastic small round cell tumour: case report with literature review].
  • However, in recent years there have been reports on desmoplastic small round cell tumors affecting other body regions, including the paratesticular area.
  • A computed tomography scan showed a para-aortic mass of 1cm.
  • Histological and immunohistochemical diagnosis confirmed a desmoplastic small round cell tumor.
  • The patient received chemotherapy.
  • Recent reviews on desmoplastic small round cell tumors affecting the paratesticular area have shown a better prognosis for tumors of this origin compared to abdominal ones.
  • We should include this lesion among the differential diagnosis of paratesticular tumors, mainly in children and adolescents.
  • [MeSH-minor] Adolescent. Adult. Cell Division. Child. Humans. Immunohistochemistry. Keratins / genetics. Male. Orchiectomy. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009. Published by Elsevier SAS.
  • (PMID = 20189431.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


22. Akramipour R, Zargooshi J, Rahimi Z: Infant with concomitant presence of hernia/hydrocele and primary paratesticular neuroblastoma: a diagnostic and therapeutic challenge. J Pediatr Hematol Oncol; 2009 May;31(5):349
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infant with concomitant presence of hernia/hydrocele and primary paratesticular neuroblastoma: a diagnostic and therapeutic challenge.
  • We report an 8-month-old boy with stage 1 neuroblastoma, whose "testicular tumor" was removed during a "radical orchiectomy" by a pediatric surgeon who encountered a scrotal mass during a hernia repair.
  • Pathologic examination of the specimen suggested seminoma and the surgeon sent the patient for cisplatin-based chemotherapy.
  • The patient is tumor free after 36 months of follow-up.
  • This case shows that in presence of hernia, distorted anatomy, and inguinal testis, paratesticular tumors can be misdiagnosed for the testis and cause great diagnostic and therapeutic difficulty.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415016.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Stewart RJ, Martelli H, Oberlin O, Rey A, Bouvet N, Spicer RD, Godzinski J, Stevens MC, International Society of Pediatric Oncology: Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J Clin Oncol; 2003 Mar 1;21(5):793-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
  • PURPOSE: To report the results of the Malignant Mesenchymal Tumors studies (MMT 84 and 89) of the International Society of Pediatric Oncology (SIOP) in males with nonmetastatic paratesticular rhabdomyosarcoma.
  • Disease was staged according to the SIOP tumor-node-metastasis staging system.
  • Treatment was stratified by stage.
  • In the MMT 89 study, males with completely resected tumors at diagnosis received less chemotherapy (vincristine and dactinomycin) than patients in the MMT 84 study (ifosfamide, vincristine, and dactinomycin).
  • Thirty-one tumors were larger than 5 cm, and 13 males were older than 10 years with a tumor larger than 5 cm.
  • CONCLUSION: Males with paratesticular RMS have an excellent prognosis except for a selected group of patients older than 10 years or with tumor greater than 5 cm.
  • Intensified chemotherapy incorporating alkylating agents for this subgroup may be preferred to the use of systematic lymphadenectomy to improve survival while minimizing the burden of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dactinomycin / therapeutic use. Ifosfamide / therapeutic use. Mesenchymoma / drug therapy. Rhabdomyosarcoma / drug therapy. Testicular Neoplasms / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Humans. Infant. Lymph Node Excision. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12610176.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide; IVA protocol; SIOP protocol
  •  go-up   go-down


24. Tröbs RB, Krauss M, Geyer C, Tannapfel A, Körholz D, Hirsch W: Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period. Klin Padiatr; 2007 May-Jun;219(3):146-51
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period.
  • Testicular and even more paratesticular tumours in children are rare.
  • Further on, we observed 3 boys with paratesticular rhabdomyosarcoma (RMS), and three with testicular and paratesticular metastases (Wilms' tumour, neuroblastoma, leukaemia).
  • Dependent on tumour histology, stage and the recommended treatment schedule postoperative chemotherapy was added.
  • Meta-analysis of the recent literature revealed that testis sparing surgery is feasible and save in prepubertal boys after exclusion of a malignant tumour.
  • However, the high rate of malignant or potentially malignant tumours suggests that high inguinal orchidectomy should remain the surgical standard of therapy.
  • [MeSH-major] Granulosa Cell Tumor / surgery. Leydig Cell Tumor / surgery. Neoplasms, Germ Cell and Embryonal / surgery. Sertoli Cell Tumor / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Diagnostic Imaging. Feasibility Studies. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Orchiectomy / methods. Retrospective Studies. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525908.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


25. Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O: Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol; 2005 Apr 20;23(12):2618-28
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
  • PURPOSE: To improve outcome for children with nonmetastatic rhabdomyosarcoma and to reduce systematic use of local therapy.
  • PATIENTS AND METHODS: Five hundred three previously untreated patients aged from birth to 18 years, recruited between 1989 and 1995, were allocated to one of six treatment schedules by site and stage.
  • Differences between EFS and OS reflected local treatment strategy and successful re-treatment for some patients after relapse.
  • Patients with genitourinary nonbladder prostate tumors had the most favorable outcome (5-year OS, 94%): the majority were boys with paratesticular tumors treated successfully without alkylating agents.
  • Patients with stage III disease treated with a novel six-drug combination showed improved survival compared with the Malignant Mesenchymal Tumor 84 study (MMT 84; 5-year OS, 60% v 42%, respectively).
  • OS was not significantly better than that achieved in the previous MMT 84 study, but 49% of survivors were cured without significant local therapy.
  • CONCLUSION: Selective avoidance of local therapy is justified in some patients, though further work is required to prospectively identify those for whom this is most applicable.
  • The value of the new six-drug chemotherapy combination is being evaluated further in a randomized study (MMT 95).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Child. Child, Preschool. Dactinomycin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Teniposide / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant mesenchymal tumor.
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Apr 20;23(12):2586-7 [15728222.001]
  • (PMID = 15728225.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 957E6438QA / Teniposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; IVA protocol; VCE protocol
  •  go-up   go-down


26. Saab R, Khoury JD, Krasin M, Davidoff AM, Navid F: Desmoplastic small round cell tumor in childhood: the St. Jude Children's Research Hospital experience. Pediatr Blood Cancer; 2007 Sep;49(3):274-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumor in childhood: the St. Jude Children's Research Hospital experience.
  • BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare, primarily intra-abdominal tumor that has a poor outcome with current therapies.
  • PROCEDURE: We retrospectively reviewed patient characteristics, presenting symptoms, tumor pathology, treatment, and outcome of 11 pediatric patients with DSRCT at our institution.
  • In eight (73%) patients, the primary tumor was abdominal or pelvic, and in one patient each, it was submental, mediastinal, and paratesticular.
  • One tumor showed rhabdomyoblastic differentiation after therapy.
  • All patients received chemotherapy; eight underwent surgical resection, seven received primary site radiation, and four received myeloablative chemotherapy with stem-cell support.
  • Two died of treatment-related toxicity, six died of disease.
  • None of the patients in whom surgery and initial chemotherapy failed to induce complete remission survived.
  • CONCLUSIONS: DSRCT is an aggressive malignancy that does not respond well to contemporary treatments, and patients who do not enter complete remission after initial chemotherapy and surgery appear to have a particularly dismal outcome.
  • Better understanding of molecular and genetic mechanisms of tumorigenesis and treatment-related changes may contribute to development of more effective therapy for DSRCT.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Neoplasms / therapy. Neoplasms, Complex and Mixed / pathology. Neoplasms, Complex and Mixed / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Oncogene Proteins, Fusion. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16685737.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EWS1-WT1 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


27. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS: Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol; 2001 Jun 15;19(12):3091-102
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The study goal was to improve outcome in children with rhabdomyosarcoma by comparing risk-based regimens of surgery, radiotherapy (RT) and chemotherapy.
  • PATIENTS AND METHODS: Eight hundred eighty-three previously untreated eligible patients with nonmetastatic rhabdomyosarcoma entered the Intergroup Rhabdomyosarcoma Study-IV (IRS-IV) (1991 to 1997) after surgery and were randomized treatment by primary tumor site, group (1 to 3), and stage (I to III).
  • Overall, patients with embryonal tumors benefited from intensive three-drug chemotherapy in IRS-IV (3-year FFS, 83%).
  • The improvement was seen for patients with stage I or stage II/III, group 1/2 disease, many of whom received VA chemotherapy on IRS-III.
  • Three-year FFS for the nonrandomized patient subsets was 75% with renal abnormalities; 81% for paratesticular, group 1 cases; and 91% for group 1/2 orbit or eyelid tumors.
  • Patients with paratesticular primaries had poorer outcomes if they were more than 10 years old (3-year FFS, 63% v 90%).
  • CONCLUSION: VAC and VAI or VIE with surgery (with or without RT), are equally effective for patients with local or regional rhabdomyosarcoma and are more effective for embryonal tumors than therapies used previously.
  • Younger patients with group 1 paratesticular embryonal tumors and all patients with group 1/2 orbit or eyelid tumors can usually be cured with VA chemotherapy along with postoperative RT for group 2 disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Radiotherapy / methods. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Dose Fractionation. Eyelid Neoplasms / mortality. Eyelid Neoplasms / pathology. Eyelid Neoplasms / therapy. Female. Humans. Infant. Male. Orbital Neoplasms / mortality. Orbital Neoplasms / pathology. Orbital Neoplasms / therapy. Prognosis. Retrospective Studies. Survival Rate. Testicular Neoplasms / mortality. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11408506.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-13539; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-29139; United States / NCI NIH HHS / CA / CA-30138; United States / NCI NIH HHS / CA / CA-30969
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


28. Bisogno G, Roganovich J, Sotti G, Ninfo V, di Montezemolo LC, Donfrancesco A, Mascarin M, Carli M: Desmoplastic small round cell tumour in children and adolescents. Med Pediatr Oncol; 2000 May;34(5):338-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumour in children and adolescents.
  • BACKGROUND: Desmoplastic small round cell tumour (DSRCT) is a rare highly aggressive neoplasm, and clinical studies are scarce.
  • PROCEDURE: We report six cases of children and adolescents (median age 14 years, range 6.9-17.5) with DSRCT (5 abdominal, 1 paratesticular) registered by the Italian Cooperative Group (ICG) for soft tissue sarcoma over a 9-year period.
  • Patients received a multidisciplinary treatment, including aggressive initial or delayed surgery and radiotherapy.
  • Chemotherapy regimen was based on the use of ifosfamide, vincristine, dactinomycin, and a few doses of antharacyclines (doxorubicin or epirubicin).
  • RESULTS: Complete surgical resection was possible only for the paratesticular tumour.
  • All patients received multidrug chemotherapy, and tumour reduction was obtained in the 4 evaluable patients.
  • CONCLUSIONS: DSRCT is a chemosensitive tumour, but survival rates remain disappointing despite aggressive multimodality therapy.
  • Our results support surgical tumour removal and radiotherapy to achieve local control.
  • Our experience and a review of the literature suggest that patients with localised abdominal tumours or a paratesticular primary may have a better prognosis.
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / radiotherapy. Abdominal Neoplasms / surgery. Adolescent. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Dactinomycin / administration & dosage. Disease-Free Survival. Humans. Ifosfamide / administration & dosage. Male. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Salvage Therapy. Survival Rate. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy. Testicular Neoplasms / surgery. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10797355.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


29. Crespo Atín V, Padilla Nieva J, Martín Bazaco J, Llarena Ibarguren R, Pertusa Peña C: [Scrotal liposarcoma]. Arch Esp Urol; 2001 Sep;54(7):729-32
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe an additional case of scrotal liposarcoma and its treatment, which was distinct from conventional treatment.
  • METHODS: The literature on paratesticular masses is reviewed with special reference to the liposarcomas.
  • An additional case of liposarcoma is described which was treated by tumor excision without involvement of the testis.
  • The diagnosis, classification and treatment of this condition are discussed.
  • RESULTS: Liposarcoma is a very uncommon tumor and its diagnosis is based on the anatomopathological findings.
  • Treatment is by orchidectomy with high ligation of the spermatic cord.
  • However, the case described herein was treated only by resection of the tumor.
  • Chemotherapy does not appear to be useful in this type of tumor.
  • CONCLUSION: In some cases of scrotal liposarcoma, the tumor can be resected without performing orchidectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11692442.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 11
  •  go-up   go-down


30. Wu HY, Snyder HM 3rd: Pediatric urologic oncology: bladder, prostate, testis. Urol Clin North Am; 2004 Aug;31(3):619-27, xi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although treatment for bladder, prostate, and testis cancer comprises a large part of adult urologic practice, the tumors that affect these organs in children are rare.
  • Rhabdomyosarcoma,which affects the bladder, prostate, vaginal, and paratesticular areas,is treated with a combination of surgery, chemotherapy, and radiation.
  • Application of the technical advances learned in adults with tumors of the bladder, prostate, and testis, combined with an understanding of the difference in tumor biology, helps urologists improve the treatment of these tumors in children.
  • [MeSH-major] Prostatic Neoplasms / therapy. Rhabdomyosarcoma. Testicular Neoplasms / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Cystectomy. Endodermal Sinus Tumor / surgery. Female. Humans. Leydig Cell Tumor / surgery. Male. Neoplasm Staging. Orchiectomy. Risk Assessment. Uterine Neoplasms / therapy. Vaginal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313070.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


31. Grande AM, Rinaldi M, Sinelli S, D'Armini AM, Viganŏ M: Heart transplantation in chemotherapeutic dilated cardiomyopathy. Transplant Proc; 2003 Jun;35(4):1516-8
MedlinePlus Health Information. consumer health - Heart Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine patients (four men) experienced postchemotherapy DCM: age at time of tumour diagnosis ranged from 1-45 years (mean 13.5 +/- 19 years); interval time between tumour and HT was 3-23 years (mean 10.8 +/- 6.6) and age at HT ranged from 10-65 years (30.8 +/- 20.1).
  • Interval between end of chemotherapy and beginning of cardiac symptoms was 5.71 +/- 4.6 years.
  • Interval between start of chemotherapy and DCM ranged from 1 month to 10 years (mean 3.15 +/- 3.6 years).
  • Tumours were Ewing sarcoma (7-year-old boy), paratesticular rabdomyosarcoma (1-year-old boy), Wilms tumor with pulmonary metastasis (3-year-old girl), bilateral breast carcinoma (45-year-old woman), uterine leiomyosarcoma (44-year-old woman), acute myelocytic leukemia (1.5-year-old boy and 17-year-old girl), and chronic myelocytic leukemia (5-year-old boy).
  • Patients with end-stage postchemotherapy DCM without evidence of tumour recurrence can safely undergo HT.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasms / classification. Neoplasms / drug therapy. Treatment Outcome


32. Merguerian PA, Chang B: Pediatric genitourinary tumors. Curr Opin Oncol; 2002 May;14(3):273-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each year advances are made in the clinical evaluation and treatment of genitourinary tumors in children.
  • In addition, information is accumulating about the long-term outcome and complications associated with treatment modalities.
  • This article reviews the 2001 literature on pediatric Wilms tumor, other renal tumors, rhabdomyosarcoma of the pelvis, paratesticular rhabdomyosarcoma, and testicular tumors.
  • The National Wilms' Tumor Study Group reported on the complications of surgery and the decreased complication rate when these procedures are performed by pediatric surgical specialists.
  • Long-term complications of treatment are also discussed, including short stature and leukemia.
  • The Intergroup Rhabdomyosarcoma Study Group reported on the results of treatment for nonmetastatic disease and the goals of the upcoming Study V, reduction of chemotherapy and radiotherapy.
  • [MeSH-minor] Child. Clinical Trials as Topic. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Male. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy. Treatment Outcome. Wilms Tumor / diagnosis. Wilms Tumor / pathology. Wilms Tumor / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981271.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


33. Cecchetto G, Guglielmi M, Inserra A, Zanetti I, Dall'Igna P, Gigante C, Carli M, Italian Cooperative Group on Soft-tissue Sarcomas: Primary re-excision: the Italian experience in patients with localized soft-tissue sarcomas. Pediatr Surg Int; 2001 Sep;17(7):532-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary re-excision: the Italian experience in patients with localized soft-tissue sarcomas.
  • Primary re-excision (PRE) is a wide, non-mutilating procedure carried out in patients with soft-tissue sarcomas (STS) when microscopic residuals are left after initial excision or when there are insufficient data on its completeness.
  • The primary sites were the extremities in 20, paratesticular 15, trunk 9, head-neck-non-parameningeal (HNnPM) 6, bladder 1, other sites in 2; the tumor (T) status was T1a in 30, T1b in 10, T2a in 9, and T2b in 4; the median interval between primary surgery and PRE was 36 days.
  • Of the 53 patients, 45 had complete histologic excision of the tumor (residuals were found in 21/45 specimens) and subsequently received chemotherapy (CT) alone: 39/45 are in their first complete remission (CR) with a median follow-up of 53 months; 6/45 (3 RMS, 3 NRSTS) relapsed, 4 locally (2 extremities, 2 trunk), and 1 of these died of progressive disease, and 2 with metastatic spread died of their disease.
  • The histologic types and the presence of residuals at PRE did not predict the failures; PRE was effective especially in extremity, trunk, and paratesticular sites, whereas its role was uncertain in large sarcomas over 5 cm in size.
  • [MeSH-major] Rhabdomyosarcoma / surgery. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11666052.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


34. Nascimento AF, Fletcher CD: Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol; 2005 Aug;29(8):1106-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The spindle cell variant of rhabdomyosarcoma (RMS) is uncommon and is most often encountered in the paratesticular region of children in whom it has a good prognosis.
  • Tumor size varied from 1.5 to 35 cm (median, 6 cm).
  • The head and neck region, including the oral cavity, parotid gland, nasopharynx, and nasal cavity, was the commonest affected area, accounting for >50% of the cases, followed by retroperitoneum, thigh, leg, subscapular area, hand, vulva, and paratesticular region (1 case each).
  • Treatment modalities included surgery, chemotherapy, and radiation.
  • One tumor was focally positive for keratins and EMA.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006807.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Myogenic Regulatory Factors; 0 / Myoglobin; 0 / S100 Proteins; 0 / myogenic factor 6; 68238-35-7 / Keratins; EC 3.6.4.1 / Myosins
  •  go-up   go-down


35. Méndez R, Arnáiz S, Montero M, Tellado M, País E, Ríos J, Vela D: [Clinical patterns of soft-tissue sarcoma in children]. Cir Pediatr; 2001 Jan;14(1):14-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical patterns of soft-tissue sarcoma in children].
  • INTRODUCTION AND OBJECTIVES: Soft tissue sarcomas are rare mesenchymal neoplasms that constitute less than 10% of all pediatric malignancies.
  • The purpose of this work is to evaluate our clinical experience with soft tissue sarcomas in uncommon sites over the past 10 years in order to delimitate the prognostic factors in survival and modalities of treatment.
  • MATERIAL AND METHODS: Between 1989 and 1998, 10 patients were diagnosed with soft tissue sarcomas in uncommon sites and treated by us over a total number of 139 pediatric neoplasms (7.19%).
  • Variables investigated included histologic findings, tumor size, age at presentation, primary site, clinical group, radiologic test performed, surgical treatment, radiotherapy and adjuvant chemotherapy, complications and survival rates.
  • RESULTS: The following histologic types of these 10 tumors were identified: 1 hemangiopericytoma in oral cavity, 2 extraosseous Ewing's sarcoma, 1 botryoid rhabdomyosarcoma of the bladder, 1 mediastinal fibrosarcoma, 1 retroperitoneal rhabdomyosarcoma, 1 paratesticular rhabdomyosarcoma, 1 cervical condrosarcoma, 1 alveolar rhabdomyosarcoma and 1 deltoid rhabdomyosarcoma.
  • Adjuvant chemotherapy with IVA was followed by radiotherapy only in four patients.
  • All the children classified in clinical groups II, III or IV needed 2nd. line regimens of chemotherapy.
  • Three patients died in the follow-up instead of the multimodal treatment.
  • 2) radiotherapy will only be necessary if margins of resection cannot control the local disease, and 3) chemotherapy have not clearly demonstrated his benefits as adjuvant therapy in clinical group I lesions but his employ is recommended in all cases because of the poor prognosis due to local recurrence.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11339112.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


36. Antón L, Pérez-Etchepare E, Soriano D, Gómez M, Barrientos G, Tracchia R: [Testicular tumors: wide spectrum in our short casuistics]. Cir Pediatr; 2010 Oct;23(4):222-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report seven cases, three germ cell tumors: a Yolk sac tumor in a child of 18 months and two mature teratomas in children between 2 and 11 years presenting as a painless testicular mass without other symptoms.
  • The treatment was radical orchiectomy in five cases.
  • Testis-sparing surgery in Leydig cell tumor and resection of the paratesticular mass was performed through scrotal.
  • The Yolk sac tumor requiring chemotherapy with good outcome.
  • Recent testicular preservation algorithms optimize and minimize the morbidity of adjuvant therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21520554.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


37. Cecchetto G, Carli M, Sotti G, Bisogno G, Dall'Igna P, Boglino C, Granata C, Antoniello L, Guglielmi M: Importance of local treatment in pediatric soft tissue sarcomas with microscopic residual after primary surgery: results of the Italian Cooperative Study RMS-88. Med Pediatr Oncol; 2000 Feb;34(2):97-101
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of local treatment in pediatric soft tissue sarcomas with microscopic residual after primary surgery: results of the Italian Cooperative Study RMS-88.
  • BACKGROUND: The goal of primary excision in soft tissue sarcomas is the complete removal of the tumor by a nonmutilating procedure.
  • However, microscopic residuals may be left after a conservative procedure because of inadequate preoperative assessment or difficulties during the operation.
  • The purpose of this report is to describe the treatment and the outcome in patients, enrolled in the Italian Cooperative Study RMS-88, with microscopic residuals after primary excision (IRS Group IIa).
  • PROCEDURE: Microscopic residuals were evident at histology in 52 of 90 patients who had a macroscopic complete primary excision: 25 rhabdomyosarcomas (RMS) and 27 nonrhabdo-soft tissue sarcomas (NRSTS).
  • Eighteen patients were treated with primary reexcision (PRE) and chemotherapy (CT) using VA or IVA regimens; 27 patients received radiation therapy (RT; 40 Gy) and IVA; 7 children in whom PRE was not feasible and RT could not be administered for age <3 years were treated with CT (IVA) alone.
  • PRE represented the treatment of choice for children <3 years of age who cannot receive RT and for paratesticular sites.
  • [MeSH-major] Neoplasm Recurrence, Local / therapy. Rhabdomyosarcoma / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10657868.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down






Advertisement